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We have previously shown that detection of autologous antibody activity to squamous cell carcinoma of the head and neck may 
be augmented by dissociation of immune complexes. Western blot analysis with autologous antibody has identified a 60 kDa 
squamous cell carcinoma of the head and neck-associated antigen in spent media and immune complex-dissociated serum 
ultrafiltrate not recognized by normal human sera. Antigen-containing fractions of spent media were eluted from anion exchange 
columns immediately after serum albumin indicating that the antigen has an acidic pI  < 4. Preparative purification of the 
squamous cell carcinoma antigen was accomplished by anion exchange of concentrated spent media (protein concentration 300 
mg/ml) followed by lectin affinity chromatography with a Triticum culgaris column. A single 60 kDa band was detected by silver 
stain and Western blot in antigen-containing fractions eluted following lectin affinity chromatography and SDS-PAGE. Final 
concentration of the antigen was determined to be 1 ~g/ml  of protein with relative activity increased 1600 x over unfraction- 
ated spent media. We conclude that a squamous cell carcinoma of the head and neck-associated antigen, detected by autologous 
antibody, is an acidic 60 kDa glycoprotein. 
Introduction 
One of the major focuses of tumor immunology has 
been the detection and characterization of tumor-asso- 
ciated antigens. By identifying antigens that are re- 
stricted to tumor cells it may be possible to bet ter  
understand the nature of the host-tumor interaction 
and tailor more effective agents for immunodiagnostic 
and therapeutic use. A variety of antibodies have been 
utilized to detect tumor-associated antigens. These an- 
tibodies have included polyclonal xenogeneic and allo- 
geneic antisera and more recently, monoclonal murine 
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and human antibodies [1-3]. Unfortunately, these anti- 
bodies have generally been found to detect normal 
cellular products rather  than tumor-restricted antigens 
when sufficiently studied. 
Studies defining tumor-associated antigens in squa- 
mous cell carcinoma of the head and neck (SCCHN) 
have yielded similar results. While the development of 
monoclonal antibodies directed against SCCHN have 
been reported [4-8], they have been found to react 
with normal cell constituents. To avoid the difficulties 
associated with the use of heteroantisera, we have 
focused our attention on the autologous immune re- 
sponse. The advantage of studying autologous antibody 
reactivity is that it may detect antigens not apparent  to 
heteroantisera. Because these antigens are produced 
by the host they may detect biologically relevant anti- 
gens that could shed light on the hos t - tumor  interac- 
tion. 
Previous studies have noted autologous antibody 
reactivity against SCCHN in 24 of 41 systems tested 
with a median titer of 1 :4  [9,10]. In the majority of 
cases, autologous antibody reactivity could only be 
detected in undiluted serum precluding further analy- 
sis. The low incidence and weak titer of autologous 
antibody to cancer has raised questions regarding the 
relevance of humoral immunity. The presence of circu- 
lating antigen in patients and the resulting formation 
of immune complexes may explain this. We have 
demonstrated that dissociation of immune complexes 
by acidification and ultrafiltration of sera augments 
autologous antibody reactivity in the majority of cases 
studied [9,11]. These findings support the hypothesis 
that autologous antibody to SCCHN and melanoma 
may be obscured by circulating antigen and that im- 
mune complexes may provide a readily accessible 
source of relevant antigen and antibody. In melanoma, 
we have noted correlations between the presence and 
titer of host-derived antibody reactivity and clinical 
course and prognosis [12,13]. Serial studies have been 
performed on 6 patients with SCCHN and correlations 
with clinical course have been noted as well [14]. Our 
work and that of others [15] would support the conclu- 
sion that circulating immune complexes may be a 
reservoir for tumor-associated antigens and antibody 
relevant to the host. 
What remains to be determined is the nature and 
biological significance of the antigens recognized by 
the host. In melanoma we have succeeded in purifying, 
to apparent homogeneity, a shed 66 kDa tumor-associ- 
ated antigen identified by autologous antibody [13,16]. 
This antigen has been noted to be an unusually acidic 
glycoprotein (pI 2-3) that is sensitive to digestion with 
trypsin and neuraminidase. We have begun to extrapo- 
late these findings to explore the nature of antigens 
recognized by patients with SCCHN. We now report 
what is to our knowledge the first successful isolation 
and purification, to apparent homogeneity, of a 
SCCHN-associated antigen identified by autologous 
antibody. 
Materials and Methods 
Cell culture and source of antigen. The acquisition, 
establishment and maintenance of SCCHN and other 
cell lines have been reported previously [9,11]. SCCHN 
cell lines were maintained in culture with minimal 
essential medium (MEM) plus 1% nonessential amino 
acids, 2 mM L-glutamine, 15% fetal bovine serum, 100 
IU/ml  penicillin and 100 /xg/ml streptomycin. Squa- 
mous cell carcinoma lines UM-SCC-17A was derived 
from the primary tumor specimen of a patient with a 
T1NOM0 SCC of the left true vocal cord, treated and 
followed in the Department of Otolaryngology at the 
University of Michigan [17]. The source of antigen was 
pooled spent tissue culture media from UM-SCC 17A, 
which had been concentrated (protein concentration 
300 mg/ml) and stored at -70°C. Antigen was also 
obtained from autologous serum ultrafiltrate obtained 
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following acid dissociation and ultrafiltration (see be- 
low). Serum ultrafiltrate was concentrated to the initial 
serum volume, dialyzed against PBS to correct pH and 
stored at -70°C. 
Protein A hemadsorption (PA). Indicator cells for 
protein A mixed hemadsorption tests were prepared by 
conjugating staphylococcal protein A (Pharmacia Fine 
Chemicals) to the surface of selected human blood 
group O-Rh positive red blood cells with 0.01% CrC13 
at pH 5.0 [18]. Target monolayers were seeded in 
micro-Terasaki assay plates and reacted with serial 
dilutions of autologous native serum, or derived frac- 
tions. After incubation of target cells with sera at 37°C, 
wells were washed 3 times with PBS containing 2% 
immunoglobulin-free fetal calf serum (FCS) at 37°C 
and 0.01 ml of an 0.15% suspension of indicator cells 
were added to each well. Plates were washed 2-4 times 
with PBS-2% immunoglobulin-free FCS after 45 min, 
and positive cells read as follows: (+)  ceils were those 
which bear a > 50% erythrocyte rosette. The endpoint 
of the assay is read as the last well with 10% of target 
ceils ( + ). 
Acid dissociation and ultrafiltration (AD&U) of 
serum. The method initially described by Sjogren et al. 
[19] was used to dissociate immune complexes in serum 
to augment autologous antibody reactivity. The analysis 
reported in this study was performed using a serum 
sample obtained 7 years after successful surgical exci- 
sion from the donor of the UM-SCC-17A cell line. 
Briefly, a 60 ml ultrafiltration chamber and Amicon 
XM-100 membrane (Amicon Corporation) were used. 
2-3 ml of prefiltered (0.45 izm, Millipore) serum was 
added to 50 ml of glycine-saline buffer, 0.1 M (pH 3.1), 
in the ultrafiltration chamber. Ultrafiltration was per- 
formed at 4°C under 10 Ib/inch 2 N 2 until the original 
volume of the test solution is reached. This was re- 
peated twice and then the preparation was washed 
three times with 50 ml PBS, and concentrated to the 
original volume of the test solution. The total time 
involved varied from 24 to 48 h depending on the 
serum used. 
Detection of isolated antigen by competitiue inhibition. 
To determine whether the isolated fraction of spent 
media contained the antigen of interest, competitive 
inhibition by the isolated antigen for antibody directed 
against autologous UM-SCC-17A cells was performed. 
Fractions tested for the presence of SCCHN-associated 
antigen were mixed at a 1:1 ratio with autologous 
antibody, incubated for 30 min at 4°C then 30 min at 
37°C and retested utilizing PA against UM-SCC-17A 
ceils (see above). A 2-fold drop in autologous antibody 
titer was considered to be indicative of the presence of 
antigen in the fraction tested. 
SDS-PAGE and transfer to nitrocellulose of SCCHN- 
associated antigens. One-dimensional SDS-PAGE was 
performed after the method of Laemmli [20] with 12.5 
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cm gels of 10% acrylamide. Antigen-containing frac- 
tions of spent media were dissolved in 0.025 M Tris-HC1 
(pH 6.8), 2% SDS, 10% glycerol, 5%. 2-mercapto- 
ethanol with 0.001% Bromphenol blue dye marker. 
Final sample volumes contained 20 /~g protein in 0.1 
ml. Electrophoresis was carried out with a current of 
20 mA until the Bromphenol blue marker reached the 
margin of the gel. The methods of Towbin et al. [21] 
were used for transfer of proteins with a Hoefer  trans- 
blot apparatus (Hoeffer Scientific Instruments, San 
Francisco, CA). Transfer was performed at 63 V for 1 
h. The nitrocellulose (0.2 ~m, Scheicher&Schuell ,  
Keene, NH) to which electrophoretic transfer was ac- 
complished was stained immunologically and with bio- 
tinylated lectins. 
Immune detection of transferred proteins. Following 
transfer to nitrocellulose, the sheet was quenched for a 
minimum of 2 h in Tris-buffered saline (TBS) (pH 7.5) 
containing plus 3% gelatin on a rocker. The nitrocellu- 
lose was overlaid with antibody diluted in TBS plus 
0.05% Tween-20 and 1% gelatin (TBS-Tween) was 
incubated on a rocker at 20°C for 3 h. The paper was 
washed with TBS-Tween for 5 min X 5. Then alkaline 
phosphatase-conjugated rabbit anti-human Ig antibody 
(CappeD, diluted with TBS-Tween was incubated with 
the nitrocellulose paper at room temperature while 
rocking for 1 h. After washing to remove unbound 
conjugate, the nitrocellulose paper was developed for 
15 min in 5-bromo-4-chloroindolyl phosphate and Ni- 
troblue tetrazolium. The reaction was stopped by re- 
moving the nitrocellulose and placing it in a fresh 
container of d H 2 0  and washing 10 rain x 2. 
Lectin binding. Following transfer of the antigen to 
nitrocellulose, the strips were quenched in TBS plus 
10% BSA and lectin binding was performed. Biotinyl- 
ated lectin (25 ~ g / m l )  (EY Laboratories, San Mateo, 
CA, and Sigma Chemical Co., St. Louis, MO) was 
diluted in TBS and incubated with the nitrocellulose 
strips for one h at room temperature.  The nitrocellu- 
lose strips were then washed in TBS and incubated 
with an avidin-biotin peroxidase complex for 1 h using 
reagents from the Vectastain ABC Kit (Vector Labora- 
tories, Burlingame, CA). Lectin binding was visualized 
using diaminobenzidine as the chromogen. 
Enzymatic digestion. Nitrocellulose-bound, partially 
purified antigen obtained following anion exchange 
chromatography (see below) and SDS-PAGE, was in- 
cubated with 5 . 1 0  -s units of neuraminidase (Vibrio 
cholera isolate, Calbiochem, San Diego, CA) in 0.5 ml 
of dilution buffer (50 mM sodium acetate, 154 mM 
NaC1, 4 mM CaCI 2 (pH 5.5)) containing 0.5 m g /m l  of 
lysozyme as a carrier protein, at 37°C for 30 min. The 
reaction was stopped by addition of 250 mM ED TA  
(pH 7.0). Following exposure to neuraminidase, the 
treated antigen was tested by immunoblotting. Partially 
purified antigen, obtained following anion-exchange 
chromatography, was subjected to digestion with a I tf 
solution of pepsin (Millipore Corp.), at pH 3.0, ~r 
trypsin (Gibco), at pH 7.5, for 16 h at 20°( ̀  prior to 
SDS-PAGE and immunoblotting. 
Preparatiue purification 
DEAE-anion-exchange chromatography. 3 ml of con- 
centrated, unfractionated spent media (protein concen- 
tration 300 mg/ml)  was applied to a 1.8 x 15.5 cm 
Whatman DE-52 weak anion-exchange column that 
had been equilibrated with 0.02 M Tris formate (pH 
8.0). The pH was changed in step-wise fashion with 0.5 
M sodium formate (pH 2.8). Fractions were collected, 
dialyzed against PBS and tested for the presence of 
antigen by competitive inhibition. 
Lectin affinity chromatography. Following anion-ex- 
change chromatography, 10 ml of antigen containing 
fractions (protein concentration 100 /xg/ml) were ap- 
plied to a 10 ml Triticum uulgaris affinity column (E-Y 
Laboratories, San Mateo, CA), pre-equilibrated with 
PBS at 4°C. The antigen was incubated on the column 
for 15 rain and the column was washed with 5 vol. of 
PBS. Antigen bound to the column was eluted with 0.5 
M N-acetylglucosamine (GIcNAc) in 0.15 M NaCI. 
Fractions were collected, dialyzed and tested for the 
presence of antigen by competitive inhibition. 
Determination of yield and actie#y. Measurement of 
protein concentration following each purification step 
was determined by the Bradford dye-binding proce- 
dure [22] or bicinchronic acid assay (micro-BCA assay, 
Pierce, Rockford, IL) with the exception of final purifi- 
cation step where the level was below the limits of 
detection and was estimated based on the appearance 
of a silver-stained SDS-PAGE gel of the antigen [23,24]. 
Assessment of activity of antigen obtained at each 
purification step was expressed as the dilution of anti- 
gen required to give the same reduction in autologous 
antibody titer against SCCHN cell line UM-SCC-17 as 
unfractionated spent media. 
Results 
Isolation of an SCCHN antigen identified by autologous 
antibody 
The specificity of the antigen detected by autolo- 
gous antibody from the donor of the UM-SCC-17A cell 
line has previously been reported [14]. Briefly, the 
antigen was noted to be present on 7 / 7  SCCHN and 
2 / 2  melanoma cell lines. Autologous antibody did not 
react with neuroblastoma, glioma, renal cell, bladder, 
or colon carcinoma cell lines, fetal fibroblasts, pooled 
lymphocytes, platelets red blood cells or fetal calf 
serum. In addition, sera from six normal individuals 
did not react with SCCHN cell lines both before and 
after immune-complex dissociation. Co-incubation of 
antibody with spent media from autologous tumor cells 
or with antigen-containing ultrafiltrate obtained from 
autologous serum by AD & U inhibited antibody bind- 
ing to UM-SCC-17 cells (Table I). Conversely, co-in- 
cubation of autologous antibody with fetal calf serum, 
tissue culture media, or spent media obtained from an 
unreactive bladder carcinoma cell line (HTB4) did not 
inhibit antibody binding. This suggests that tumor-asso- 
ciated antigens detected by A D & U  antibody are pre- 
sent in the sera of patients with SCCHN and are also 
shed or secreted by their tumor cells in culture. 
We have focused our current study on antigen re- 
covered in spent media as this represents a continu- 
ously accessible source of antigen for study. Western 
blot analysis (Fig. 1) with immune complex-dissociated 
autologous sera (lane C) has identified an antigen with 
a molecular weight of 60 kDa in spent media. This 
antigen is not recognized by normal human (lane A) or 
native autologous sera (lane B). A similar 60 kDa band 
was also detected in autologous serum ultrafiltrate 
(Fig. 7). As is illustrated in Fig. 2, binding of antibody 
to this antigen was diminished by absorption of sera 
with the autologous SCCHN cell line UM-SCC-17A 
(lane 17A) but not after absorption with fetal fibro- 
blasts (lane FF) when compared  to unabsorbed control 
antibody (lane C). 
Anion-exchange chromatography 
Anion-exchange chromatography was employed as 
the initial step in separating the antigen from other 
components  present  in spent media. As illustrated in 
Fig. 3b, autologous antibody reactivity was reduced by 
samples obtained from fractions 86-92. This corre- 
sponds to the small shoulder of  the large peak noted 
on the chromatograph (see " * " ,  Fig. 3a). No other 
fractions were noted to contain the antigen. The loca- 
tion of the antigen-containing fractions which eluted 
TABLE I 
Competitve inhibition of autologous antibody reactivity against UM- 
SCC-17 
AD&U, autologous sera obtained following acid dissociation and 
ultrafiltration (see Materials and Methods); +M/17A, unfraction- 
ated spent media from UM-SCC-17A; +ULF, autologous eluate 
obtained following ultrafiltration; +FCS, fetal calf serum; +M, 
unconditioned tissue culture media; +HTB4, spent media from an 
unrelated bladder carcinoma cell line. 
Sera Maximum antibody titer 
Native 0 
AD&U 1 : 2048 
+ M/17A 1:256 
+ ULF 1 : 16 
+ M 1 : 2048 
+ FCS 1 : 2048 
+ M/HTB4 1 : 2048 
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Fig. 1. Western blot analysis of spent media from UM-SCC-17A. 
Autologous immune complex dissociated sera detected a 60 kDa 
antigen in spent media (lane C). The antigen was not detected with 
normal human sera (lane A) or native autologous sera (lane B). 
after bulk serum albumin indicating that this antigen 
has an acidic p I  < 4. 
Lectin binding 
Following anion-exchange chromatography, binding 
by a panel of biotinylated lectins to the antigen was 
evaluated. Binding was evaluated visually and the rela- 
tive intensity of binding expressed on a four point scale 
(0 to + 3). As summarized in Table II, binding by 9 of 
13 biotinylated lectins to the antigen was noted. 
Lectin affinity chromatography 
Lectin binding was noted to be quite strong with 
Triticum vulgaris (see above and Table II). Further  
purification of the antigen was performed with an 
affinity column of that lectin (see Materials and Meth- 
ods). Shown in the Fig. 4, activity, detected by competi-  
tive inhibition, was recovered in fractions 27-31, fol- 
lowing elution with 0.5 M GlcNAc (see arrow). 
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Fig. 2. Western blot analysis of SCCHN antigen. Partially purified 
antigen obtained following anion exchange chromatography (see Fig. 
4) was subjected to Western blot analysis and immunoblot with 
autologous antibody. As noted previously (Fig. 2), a 60 kDa band is 
noted (lane C). Preincubation of antibody with autologous cell line 
UM-SCC-17A (lane 17A) diminished binding. No reduction in bind- 
ing was noted following preincubation with fetal fibroblasts (lane 
FF). The excessive width of the bands are due to intentional over- 
loading of the gel to better aid in detecting differences. 
Enzymatic digest ion of SCCHN antigen 
As illustrated in Fig. 5, exposure of partially purified 
antigen to pepsin and trypsin, for 16 h at 20°C, did not 
ablate recognition of the 60 kDa band by autologous 
antibody, when compared to control. Of note, follow- 
ing trypsin digestion a new band, detected by autolo- 
gous antibody, was present at 55 kDa. Exposure to 
neuraminidase did not ablate recognition of the anti- 
gen by autologous antibody. 
Antigen purification 
Preparative purification of the antigen was accom- 
plished by anion exchange followed by lectin affinity 
chromatography on a Triticum I~ulgaris column. As 
illustrated in Fig. 6, spent media and antigen-contain- 
ing fractions obtained following sequential anion ex- 
change and lectin affinity chromatography were sub- 
jected to SDS-PAGE and silver stain. Following lectin 
affinity chromatography, a single protein band is noted 
at 60 kDa. No other bands previously noted in unfrac- 
tionated spent media or following anion-exchange 
chromatography are seen. It is possible that other 
contaminants are still present but are below the level 
of detection with silver stain. Overloading of the gel 
may demonstrate this; however, the homogeneity of 
this material will only be determined if protein se- 
quencing reveals a single peptide. Further confirmation 
that the antigen of interest had been purified is illus- 
trated in Fig. 7. where a Western blot of the same 
antigenic material, run concurrently, again demon- 
strates a similar, single 60 kDa band detected by autol- 
ogous antibody. This band also corresponds to a similar 
band noted in serum ultrafiltrate obtained following 
acid dissociation and ultrafiltration. 
Measurement of antigen activity and protein con- 
centration following each purification step is shown in 
Table III. Antigen activity only increased from 1300 × 
to 1600 × following lectin affinity chromatography. As 
seen in Table Ilk the antigen was detected in a broad 
peak across a number of fractions which may have lead 
to dilution and loss of antigen following elution from 
the lectin column. Determination of the protein con- 
centration following lectin affinity chromatography 
failed to reveal any detectable protein as measured by 
both the Bradford dye-binding procedure and micro- 
BCA assay. Based on the detection of a single faint 
band by silver stain, we estimate that the final concen- 
tration of antigen was approximately 1 ~zg/ml [25]. 
Discussion 
The primary impetus for these studies has been the 
observation that patients with SCCHN and other ma- 
lignant tumors produce an antibody directed against 
their own tumor [9,11,18]. Evaluation of the autologous 
immune response has been impeded by the low inci- 
dence and titer of antibody in native sera. Our ability 
to consistently augment autologous antibody titers by 
acidification and ultrafiltration of serum has allowed 
these studies to proceed and lends support to the 
hypothesis that circulating immune complexes are a 
reservoir for tumor-associated antigens and antibody 
relevant to the host. Of the 8 SCCHN and 21 melanoma 
systems studied, augmented autologous antibody di- 
rected against the patient's own tumor has been found 
following A D & U  in all but one case. It would appear 
that autologous antibody directed against SCCHN and 
melanoma is the rule rather than the exception. 
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Fig. 3. Anion-exchange chromatography of spent media. 3 ml of concentrated spent media (final protein concentration 300 mg/ml) was applied 
to a 1.8 × 15.5 cm Whatman DE-52 weak anion-exchange column that had been equilibrated with 0.02 M Tris formate (pH 8.0). The pH was 
changed in stepwise fashion with 0.5 M sodium formate (pH 2.8). Fractions were collected, dialyzed against PBS and tested for the presence of 
antigen by competitive inhibition. (b) Competitive inhibition of autologous antibody reactivity following anion-exchange chromatography. 
Autologous antibody reactivity was reduced by samples obtained from factions 86-91 (Fig. 4b). This corresponds to the second small shoulder on 
the major peak noted on the chromatograph (see "*",  Fig. 4a). No other fractions were noted to contain the antigen. The location of the 
antigen-containing fractions which eluted after bulk serum albumin suggests that this antigen is acidic with a pI  < 4. Control serum (C) is noted 
to have a maximum titer of 1:2048. The addition of unfractionated spent media (SM) reduced autologous antibody titers to 1:256. 
different natural histories, clinical courses etc. It may 
be argued that melanoma and SCCHN represent two 
opposite ends of the spectrum in regard to cancer 
immunobiology. Melanoma is perhaps the most im- 
munogenic cancer studied with well documented in- 
stances of spontaneous regression. SCCHN, on the 
other hand, has a natural history that is more fre- 
quently associated with immunosuppression [26]. Be- 
cause SCCHN represents the 'other end of the spec- 
trum' we extended our serologic studies in that direc- 
tion. Determination of the similarities and differences 
that exist in the host immune response to these two 
very different cancers may lead to a better overall 
understanding of the host-tumor interaction. Our re- 
suits indicate that, as with melanoma, autologous anti- 
body reactivity to SCCHN can be enhanced by dissoci- 
ation of immune complexes and that fluctuations in 
autologous antibody titers show correlations with clini- 
cal course [9,14]. The fact that similar observations can 
be made in two such disparate tumors invites further 
investigation and comparison. 
Because the source of antibody is serum, evaluation 
of the distribution of the antigen has been limited. 
Immunohistologic analysis is precluded by the large 
amount of sera required and the difficulty in charac- 
terizing specificity using human sera on human tissues. 
As a consequence, we and others have performed 
specificity analysis to evaluate antibody reactivity 
TABLE II 
Lectin binding to SCCHN antigen 
0, absent; +,  faint; + +, present; + + +, strong. 
Lectin Binding Known binding oligosaccharide 
Riticum vulgaris + + + 
Canavalia ensiformis + + 
Dolichos biflorus + + 
Arachis hypogaea 0 
Lycopersicon esculentum + 
Phytolacca americana 0 
Glycine max 0 
Erythina cristagalli + + 
Vicia villosa + + 
Griffonia simplicifolia I1 + + + 
Griffonia simplicifolia I-B4 0 
Maackia amurensis + + 
Ricin communis + 
GIcNAc(/3(1,4)GIcNAc) 2 >/3-GIcNAc, a-NeuAc (sialic acid) 
a-man > a-GIc 
GalNAc(1,3)GalNAc 
Gal/3(1,3)GalNAc > Gal 
GIcNAc(/3(1,4)GIcNAc) 1_3 
GIcNAc(fl(1,4)GlcNAc)z_5 = (Gal(/3(1,4)GIcNAc)2_5 
a- and/3-GalNAc 




NANA a(2,3) Gal fl(1,4)Glc 
D-Gal-/3(1,3) GalNAc 
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against a range of neoplastic and non-neoplastic cell 
lines. Specificity analysis of UM-SCC-17 and six other 
autologous systems has been previously reported [9,14] 
and have demonstrated a similar degree of reactivity. 
All appear  to be detecting a class II antigen that is 
present  on SCCHN and melanoma cell lines but not on 
normal cell constituents. While utilization of additional 
cell lines would be of interest it will not aid in the 
determination of the antigen's composition. Our suc- 
cess in purifying the antigen to apparent  homogeneity 
will now permit  evaluation of its composition. 
We concentrated our efforts on the isolation and 
characterization of the antigen present  in spent tissue 
culture media as it provides an unlimited and repeti- 
tively accessible source of antigen for study. While it 
may be argued that the antigen present in spent tissue 
culture media may be different than that bound to the 
antibody in serum, the evidence we have to date would 
argue that they are the same. Competitive inhibition 
with antigen obtained from serum, spent media or 
whole cells reduced binding of antibody to autologous 
SCCHN cells. Finally, a Western blot of spent media 
and serum ultrafiltrate revealed the same 60 kDa anti- 
gen (Fig. 7). 
As illustrated in Fig. 6, we have succeeded in purify- 
ing, to apparent  homogeneity, a SCCHN-associated 
antigen, identified by autologous antibody, by anion-ex- 
change followed by lectin affinity chromatography with 
a Triticum vulgaris column. Following lectin affinity 
chromatography, a single protein band, previously de- 
tected by Western blot of unfractionated spent media, 
was noted at 60 kDa. No other bands previously seen 
in unfractionated spent media or following anion-ex- 
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Fig. 4. Lcctin affinity chromatography 4 ml of antigen obtained 
following anion exchange chromatography was applied to a I0 ml 
sepharose column bound with rriticum c'ulgarLs ( E - Y  Laboratories, 
San Mateo, CA) and allowed to equilibrate for 30 min. Antigen 
binding to the column was e]uted (see arrow) with 0.5 M G]cNAc, 
dialyzed and tested for the presence of antigen by competitive 
inhibition. Antigen was detected in elution fractions 27-31. Control 
serum (C) is noted to have a maximum titer of 1:2048. The addition 
of unfractionated spent media (SM) reduced autologous antibody 
titers to 1:256. 
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Fig. 5. Enzymatic digestion of SCCHN antigen. Preincubation of 
partially purified SCCHN antigen obtained following anion-exchange 
chromatography with pepsin (lane P) or trypsin (lane T) did not 
ablate recognition of the antigen, detected by autologous antibody, 
when compared to control (lane C). Following exposure to trypsin a 
new band ( ~  55 kDa) is noted. Exposure of the antigen to neu- 
raminidase prior to SDS-PAGE (lane N) did not alter recognition of 
the antigen by autologous antibody when compared m control (lane 
C). The excessive width of the bands are due to intentional overload- 
ing of the gel to better aid in detecting differences. 
the purified antigen again revealed a single 60 kDa 
band of similar size and shape (Fig. 7). It is possible 
that other contaminants are still present but are below 
the level of detection with silver stain. Overloading of 
the gel may demonstrate  this; however, the absolute 
homogeneity of this material will be confirmed if pro- 
tein sequencing reveals a single peptide. Measurement  
of protein concentration following each purification 
step is shown Table III. Determinat ion of the protein 
concentration following lectin affinity chromatography 
is difficult as the level was below the limits of detection 
of the two assays used. Based on the detection of a 
single faint band by silver stain, we estimate that the 
final yield of antigen was approximately 12 ~g [25]. 
The low concentration of detectable protein adds addi- 
tional weight to our belief that other contaminating 
proteins have been removed. While the final protein 
concentration was small (1 /xg/ml), the relative anti- 
genic activity increased 1600 x when compared to un- 
fractionated spent media. This represents the first suc- 
cessful isolation and purification, to apparent homo- 
geneity, of a SCCHN-associated antigen recognized by 
the host. 
Initial characterization of the isolated SCCHN-asso- 
ciated antigen indicates that it is an acidic glycoprotein 
based on anion-exchange and lectin affinity chromatog- 
raphy. As illustrated in Table II, lectin binding was 
noted to 9 of 13 biotinylated lectins. The strongest 
binding was noted with Triticum vulgaris and Griffonia 
simplicofolia H. Binding to these two lectins is consis- 
tent with the presence of a /3-(1 ~ 4)-linked oligomer 
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Fig. 6. SDS-PAGE analysis of each step of purification of a 
SCCHN-associated antigen. Silver stain of a gel of unfractionated 
spent tissue culture media (lane A), and following isolation by 
anion-exchange (lane B) and lectin affinity (lane C) chromatography. 
Following lectin affinity chromatography a single protein band is 
noted at 60 kDa. No other bands previously noted in unfractionated 
spent media or following anion-exchange chromatography are seen. 
Due to the large quantity of protein in unfractionated spent media it 
was diluted 1 : 20 before being run on the gel. 
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Fig. 7. Western blot analysis of SCCHN antigen. Antigen obtained 
from serum ultrafiltrate (lane A) or following lectin affinity chro- 
matography (lane B) was subjected to Western blot analysis and 
immunoblot with autologous antibody. A single band at 60 kDa is 
noted in both lanes corresponding to the protein band seen following 
silver stain (see Fig. 7). 
of N-acetyl-D-glucosamine on the antigen [27] an ob- 
servation which is confirmed by our ability to subse- 
quently increase the specific antigenic activity by 
TABLE III 
Purification of  a 60 kDa SCCHN-associated antigen 
Purification step Volume Protein Relative 
(ml) (mg/ml)  activity a 
Spent media 3 300 1 
Anion exchange 20 0.16 1300 
Lectin 12 0.001 b 1600 
a Based upon dilution of antigen required to give same reduction in 
autologous antibody titer against SCCHN cell line UM-SCC-17A 
as unfractionated spent media. 
b Estimate based upon single band on silver stain. 
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Triticum t.,ulgaris affinity purification. Enzymatic diges- 
tion of partially purified antigenic material with trypsin 
or pepsin did not ablate recognition of the antigen by 
autologous antibody. Of additional note, exposure of 
the antigen to neuraminidase did not affect dectection 
by autologous antibody. This would suggest that sialic 
acid is not part of the antigenic epitope. However, 
given its acidic nature (p l  < 4) it is quite likely that 
sialic acid is a component of the antigen. 
The cross reactivity of the autologous SCCHN anti- 
body with melanoma-derived antigenic material indi- 
cates that similar antigens are present on both tumor 
types. Until the protein and carbohydrate composition 
of the melanoma and SCCHN antigens are determined 
the similarities and differences between these antigens 
will not be known. While cross-reactivity of the SCCHN 
and melanoma-associated antigen has been docu- 
mented, significant differences have been noted as 
well. The distribution of the melanoma-associated anti- 
gen, defined by sera from melanoma patients, was 
much broader with cross reactivity noted against 
melanoma, glioma, renal cell carcinoma, neuroblas- 
toma, and head and neck carcinoma cell lines [13]. In 
addition, many more lectins were noted to bind to the 
SCCHN antigen suggesting a distinct carbohydrate 
composition. Furthermore, in contrast to melanoma, 
recognition of the SCCHN-associated antigen by autol- 
ogous antibody was not ablated by exposure to neu- 
raminidase or trypsin. A 16 h exposure of the SCCHN 
antigen to trypsin did not ablate the 60 kDa band. 
Conversely, exposure of the melanoma-associated anti- 
gen to trypsin for only 30 min ablated recognition of 
the 66 kDa antigen by autologous antibody and led to 
the development of a new 24 kDa band [13]. 
Other investigators are beginning to explore the 
nature of tumor-associated antigens that elicit T-cell- 
mediated immunity in patients with cancer. Van der 
Bruggen et al. [28] recently reported the successful 
cloning of a gene encoding an antigen recognized by 
cytotoxic T lymphocytes in patients with melanoma. 
Those findings complement our results whose signifi- 
cance lies in the ability of the antigen to elicit a 
humoral response in patients with SCCHN. The ulti- 
mate goal of all these studies is to delineate the signifi- 
cance and biologic role of tumor-associated antigens 
that are immunogenic to the host. As a better under- 
standing emerges, it may be possible to develop tumor 
vaccines for the treatment or prevention of cancer. 
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